BRIEF-Caladrius Biosciences’ Prospective Merger Partner, Cend Therapeutics, Announces Collaboration Agreement With Roche

Reuters
10 Aug 2022

Aug 10 (Reuters) - Caladrius Biosciences Inc :

* CALADRIUS BIOSCIENCES’ PROSPECTIVE MERGER PARTNER, CEND THERAPEUTICS, ANNOUNCES COLLABORATION AGREEMENT WITH ROCHE TO EVALUATE CEND-1 IN COMBINATION WITH IMMUNOTHERAPY TO TREAT PANCREATIC CANCER

* CALADRIUS BIOSCIENCES INC - AGREEMENT ACCELERATED BY CALADRIUS' INITIAL INVESTMENT IN CEND

* CALADRIUS- ROCHE WILL BE RESPONSIBLE FOR OPERATIONAL MANAGEMENT OF TRIAL WHILE CEND AND ROCHE SHARE EQUALLY IN COSTS OF CEND-1 TREATMENT ARMS IN STUDY

Source text for Eikon: Further company coverage:

((reuters.briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10